The JAK inhibitor, ruxolitinib, inhibited STAT3 phosphorylation, increased CD38 expression in MM cells, and enhanced the antibody-dependent cellular cytotoxicity (ADCC) function of the anti-CD38 antibody DARA [116]. The gene discussed is CD38; the disease is Miyoshi myopathy.